TY - JOUR
T1 - A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
AU - Osher, Esther
AU - Shalabna, Eiman
AU - Klausner, Joseph M.
AU - Greenman, Yona
AU - Stern, Naftali
AU - Shibolet, Oren
AU - Scapa, Erez
AU - Yakir, Oz
AU - Shor, Dana Ben Ami
AU - Bar-Yishay, Iddo
AU - Shamai, Sivan
AU - Sofer, Yael
AU - Lubezky, Nir
AU - Goykhman, Yaacov
AU - Lahat, Guy
AU - Wolf, Ido
AU - Pelles, Sharon
AU - Aizic, Asaf
AU - Blachar, Arye
AU - Geva, Ravit
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the medical records of 95 consecutive patients diagnosed with PNETs who underwent surgery at our medical center between 1997 and 2017. The retrieved information included patient demographics, pathology reports, treatments, and oncological outcomes. Results: 95 consecutive potentially suitable patients were identified. The 78 patients with PNETs who underwent surgery and for whom there was adequate data were included in the analysis. Their mean ± standard deviation age at diagnosis was 57.4 ± 13.4 years (range 20–82), and there were 50 males (64%) and 28 females (36%). 23 patients (30%) had LN metastases (N1). The 2.5- and 5-year disease-free survival (DFS) rates for the entire cohort were 79.5% and 71.8%, respectively, and their 2- and 5-year overall survival (OS) rates were 85.9% and 82.1%, respectively. The optimal value of the LNR was 0.1603, which correlated with the outcome (2-year OS p = 0.002 HR = 13.4 and 5-year DFS p = 0.016 HR = 7.2, respectively, and 5-year OS and 5-year DFS p = 0.004 HR = 9 and p = 0.001 HR = 10.6, respectively). However, the multivariate analysis failed to show that the LNR was an independent prognostic factor in PNETs. Patients with PNETs grade and stage are known key prognostic factors influencing OS and DFS. According to our results, LNR failed to be an independent prognostic factor.
AB - The objective of this study was to determine the prognostic value of lymph node (LN) involvement and the LN ratio (LNR) and their effect on recurrence rates and survival in patients with pancreatic neuroendocrine tumors (PNETs) undergoing surgery. This single-center retrospective study reviewed the medical records of 95 consecutive patients diagnosed with PNETs who underwent surgery at our medical center between 1997 and 2017. The retrieved information included patient demographics, pathology reports, treatments, and oncological outcomes. Results: 95 consecutive potentially suitable patients were identified. The 78 patients with PNETs who underwent surgery and for whom there was adequate data were included in the analysis. Their mean ± standard deviation age at diagnosis was 57.4 ± 13.4 years (range 20–82), and there were 50 males (64%) and 28 females (36%). 23 patients (30%) had LN metastases (N1). The 2.5- and 5-year disease-free survival (DFS) rates for the entire cohort were 79.5% and 71.8%, respectively, and their 2- and 5-year overall survival (OS) rates were 85.9% and 82.1%, respectively. The optimal value of the LNR was 0.1603, which correlated with the outcome (2-year OS p = 0.002 HR = 13.4 and 5-year DFS p = 0.016 HR = 7.2, respectively, and 5-year OS and 5-year DFS p = 0.004 HR = 9 and p = 0.001 HR = 10.6, respectively). However, the multivariate analysis failed to show that the LNR was an independent prognostic factor in PNETs. Patients with PNETs grade and stage are known key prognostic factors influencing OS and DFS. According to our results, LNR failed to be an independent prognostic factor.
KW - ki-67
KW - lymph node ratio
KW - neuroendocrine tumor
KW - pancreatic
UR - http://www.scopus.com/inward/record.url?scp=85148898527&partnerID=8YFLogxK
U2 - 10.3390/biomedicines11020407
DO - 10.3390/biomedicines11020407
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36830943
AN - SCOPUS:85148898527
SN - 2227-9059
VL - 11
JO - Biomedicines
JF - Biomedicines
IS - 2
M1 - 407
ER -